Immatics (IMTX) Stock Price, News & Analysis

Company Overview

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Key Stats

• Today's Range: $6.79 to $7.20
• 50-Day Range: $6.73 to $9.88
• 52-Week Range: $6.68 to $13.77
• Volume: 593,521 shs
• Average Volume: 501,818 shs
• Market Capitalization: $817.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.67
• Consensus Rating: Buy

Immatics Stock Analysis - MarketRank™

Immatics scored higher than 28% of companies evaluated by MarketBeat, and ranked 811th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Immatics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immatics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immatics are expected to decrease in the coming year, from ($0.80) to ($1.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immatics is -10.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immatics is -10.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immatics has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.86% of the outstanding shares of Immatics have been sold short.

Short Interest Ratio / Days to Cover

Immatics has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Immatics has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immatics does not currently pay a dividend.

Dividend Growth

Immatics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.86% of the outstanding shares of Immatics have been sold short.

Short Interest Ratio / Days to Cover

Immatics has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Immatics has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.15

News Sentiment

Immatics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Immatics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for IMTX on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immatics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of Immatics is held by insiders.

Percentage Held by Institutions

64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMTX Stock Analysis - Frequently Asked Questions

How have IMTX shares performed this year?

Immatics' stock was trading at $10.53 at the start of the year. Since then, IMTX stock has decreased by 34.9% and is now trading at $6.85.
View the best growth stocks for 2024 here.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.13. The business had revenue of $7.60 million for the quarter, compared to the consensus estimate of $13.28 million. Immatics had a negative net margin of 47.94% and a negative trailing twelve-month return on equity of 15.90%.

Who are Immatics' major shareholders?

Top institutional shareholders of Immatics include Wellington Management Group LLP (8.11%), Vestal Point Capital LP (3.14%), Braidwell LP (1.38%) and Frazier Life Sciences Management L.P. (1.13%).

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Broadcom (AVGO), Datadog (DDOG), Advanced Micro Devices (AMD), Moderna (MRNA), Cloudflare (NET) and QUALCOMM (QCOM).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMTX
• CUSIP: N/A
• CIK: 1809196
• Web: www.immatics.com
• Phone: 4.97072E+12
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.67
• High Stock Price Target: $19.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +143.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-104,980,000.00
• Net Margins: -47.94%
• Pretax Margin: -41.19%
• Return on Equity: -15.90%
• Return on Assets: -9.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.98
• Quick Ratio: 3.98

Sales & Book Value

• Annual Sales: $115.50 million
• Price / Sales: 7.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.88 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 119,356,000
• Free Float: 115,417,000
• Market Cap: $817.59 million
• Optionable: Optionable
• Beta: 0.74